Single Dose of Psilocybin for Severe Treatment-Resistant Depression

Dr. Aaronson reports grants and nonfinancial support (supply of drug) from COMPASS Pathways during the conduct of the study and personal fees from Genomind, LivaNova, Neuronetics, and Sage Therapeutics outside the submitted work. Dr. Miller reports personal fees from COMPASS Pathways during the conduct of the study. Dr. LaPratt reports grants from COMPASS Pathways during the conduct of the study. Dr. Lauterbach reports study support from Sheppard Pratt/COMPASS Pathways and one-third ownership of Brain Educators outside the submitted work. Dr. Suppes reports stock options with Psilotec and one-time service on an advisory board for MindMed outside the submitted work. Dr. Sackeim serves as a consultant to Cerebral Therapeutics Inc., Holmusk Inc, LivaNova PLC, MECTA Corporation, Neurolief LTD, NeuroInsights Inc, Neuronetics Inc, Parow Entheobiosciences LLC, and SigmaStim LLC; he serves on the advisory boards of LivaNova PLC, Neuronetics Inc, and SigmaStim LLC; he receives honoraria and royalties from Elsevier, Inc. and Oxford University Press; he is the inventor on nonremunerative U.S. patents for Focal Electrically-Administered Seizure Therapy (FEAST) (US8712532), titration in the current domain in ECT (US9789310), and the adjustment of current in ECT devices (US10583288), each held by SigmaStim LLC; he is also the originator of magnetic seizure therapy (MST). The remaining authors report no financial relationships with commercial interests.